Literature DB >> 17560593

The nature and consequences of intra- and inter-vaccine interference.

E Vidor1.   

Abstract

Vaccine interference may be intra- or inter-vaccine in nature. Intra-vaccine interference is determined by the nature and dose of the individual vaccine valences, the nature and quality of any additives and the pharmaceutical formulation of the product. Additionally, vaccinee factors including the presence of pre-existing immunity, the stage of immunological maturation, genetic and environmental background may also determine interference. The vaccine schedule and mode of delivery are further contributory factors. In practice, the phenomenon of vaccine interference argues that individual vaccines should not be combined or associated in the absence of specific data sheet recommendations to do so.

Mesh:

Substances:

Year:  2007        PMID: 17560593     DOI: 10.1016/j.jcpa.2007.04.014

Source DB:  PubMed          Journal:  J Comp Pathol        ISSN: 0021-9975            Impact factor:   1.311


  15 in total

1.  Immune-based approaches to the prevention of mother-to-child transmission of HIV-1: active and passive immunization.

Authors:  Barb Lohman-Payne; Jennifer Slyker; Sarah L Rowland-Jones
Journal:  Clin Perinatol       Date:  2010-12       Impact factor: 3.430

Review 2.  The challenge of assessing infant vaccine responses in resource-poor settings.

Authors:  Katie L Flanagan; Sarah Burl; Barbara L Lohman-Payne; Magdalena Plebanski
Journal:  Expert Rev Vaccines       Date:  2010-06       Impact factor: 5.217

3.  Enzyme digests eliminate nonfunctional Env from HIV-1 particle surfaces, leaving native Env trimers intact and viral infectivity unaffected.

Authors:  Ema T Crooks; Tommy Tong; Keiko Osawa; James M Binley
Journal:  J Virol       Date:  2011-04-06       Impact factor: 5.103

4.  A hybrid multistage protein vaccine induces protective immunity against murine malaria.

Authors:  Balwan Singh; Monica Cabrera-Mora; Jianlin Jiang; Alberto Moreno
Journal:  Infect Immun       Date:  2012-01-17       Impact factor: 3.441

5.  Baculovirus-vectored multistage Plasmodium vivax vaccine induces both protective and transmission-blocking immunities against transgenic rodent malaria parasites.

Authors:  Masanori Mizutani; Mitsuhiro Iyori; Andrew M Blagborough; Shinya Fukumoto; Tomohiro Funatsu; Robert E Sinden; Shigeto Yoshida
Journal:  Infect Immun       Date:  2014-08-04       Impact factor: 3.441

6.  Development and application of a multiplex assay for the simultaneous measurement of antibody responses elicited by common childhood vaccines.

Authors:  Hannah L Itell; Erin P McGuire; Petronella Muresan; Coleen K Cunningham; Elizabeth J McFarland; William Borkowsky; Sallie R Permar; Genevieve G Fouda
Journal:  Vaccine       Date:  2018-08-04       Impact factor: 3.641

7.  Increased Immune Response Variability during Simultaneous Viral Coinfection Leads to Unpredictability in CD8 T Cell Immunity and Pathogenesis.

Authors:  Laurie L Kenney; Markus Cornberg; Alex T Chen; Sebastien Emonet; Juan Carlos de la Torre; Liisa K Selin
Journal:  J Virol       Date:  2015-08-12       Impact factor: 5.103

8.  Immune approaches for the prevention of breast milk transmission of HIV-1.

Authors:  Barbara Lohman-Payne; Jennifer Slyker; Sarah L Rowland-Jones
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

9.  Balanced Cellular and Humoral Immune Responses Targeting Multiple Antigens in Adults Receiving a Quadrivalent Inactivated Influenza Vaccine.

Authors:  Esther Dawen Yu; Alba Grifoni; Aaron Sutherland; Hannah Voic; Eric Wang; April Frazier; Natalia Jimenez-Truque; Sandra Yoder; Sabrina Welsh; Stacey Wooden; Wayne Koff; Buddy Creech; Alessandro Sette; Ricardo da Silva Antunes
Journal:  Vaccines (Basel)       Date:  2021-04-23

10.  Immunogenicity of individual vaccine components in a bivalent nicotine vaccine differ according to vaccine formulation and administration conditions.

Authors:  Katherine E Cornish; Sabina H L de Villiers; Marco Pravetoni; Paul R Pentel
Journal:  PLoS One       Date:  2013-12-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.